Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphomaWyndham H. Wilson, Louis M. Staudt, Roland Schmitz et al.|Nature Medicine|2015Cited by 1.1k
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphomaThomas E. Witzig, Thomas M. Habermann|Leukemia|2010Cited by 299
Non‐<scp>H</scp>odgkin lymphoma subtype distribution, geodemographic patterns, and survival in the <scp>US</scp>: A longitudinal analysis of the <scp>N</scp>ational <scp>C</scp>ancer <scp>D</scp>ata <scp>B</scp>ase from 1998 to 2011Mohammed Al‐Hamadani, Ronald S. Go, Thomas M. Habermann et al.|American Journal of Hematology|2015Cited by 280
Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman diseaseGaurav Goyal, Ronald S. Go, Aishwarya Ravindran et al.|Haematologica|2019Cited by 215
Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphomaJames R. Cerhan, Corinne Haïoun, Sonja I. Berndt et al.|Nature Genetics|2014Cited by 175